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Background:  Cardiac magnetic resonance imaging (CMRI) quantitative myocardial perfusion reserve index (MPRI) has been shown to predict 
prognosis in women with persistent chest pain and no obstructive coronary artery disease. A prior study of healthy men revealed that regadenoson 
produces higher MPRI than adenosine but differences disappear after adjusting for heart rate (HR). We hypothesized that adenosine and 
regadenoson have similar vasodilator efficacy in women.
Methods:  306 women underwent 1.5 T CMRI with rest-stress perfusion. Adenosine vs regadenoson was given based on clinical history. MPRI by 
CAAS MRV 3.3 software (Pie Medical Imaging) was assessed as a ratio of upslopes in the global, subendocardial, subepicardial, and midventricular 
(6 segments) myocardium. T-tests and analysis of covariance using T-adjustment were performed.
results:  Regadenoson produced higher unadjusted MPRI than adenosine (Table). When adjusted for HR and rate-pressure-product (RPP), the 
differences in MPRI between the two agents persisted. Weight and peak HR were higher in the regadenoson group.
conclusion:  In women undergoing stress CMRI for evaluation of persistent chest pain and no obstructive coronary artery disease, adjusted and 
unadjusted MPRIs were unexpectedly higher in the group who received regadenoson compared to adenosine. This finding may reflect referral bias 
and limitations of the MPRI approach and suggests that studies should not attempt to compare MPRIs performed with different agents.
Myocardial Perfusion Reserve Index (MPRI) with Adenosine and Regadenoson Stress
Adenosine (n=224) Regadenoson (n=82) P value
Peak HR (beats/min) 97.12 ± 16.34 109.0 ± 14.67 <0.0001
HR change from rest (beats/min) 28.86 ± 14.79 39.03 ± 13.16 <0.0001
Weight (kg) 72.33 ± 16.88 79.59 ± 19.74 0.0144
Global MPRI
Unadjusted*
Adjusted for RPP**
Adjusted for HR**
1.74 ± 0.41
1.72 ± 0.03
1.73 ± 0.03
2.23 ± 0.59
2.21 ± 0.06
2.17 ± 0.06
<0.0001
Subendocardial MPRI
Unadjusted*
Adjusted for RPP**
Adjusted for HR**
1.58 ± 0.36
1.56 ± 0.03
1.58 ± 0.03
1.94 ± 0.45
1.94 ± 0.05
1.91 ± 0.05
<0.0001
Subepicardial MPRI
Unadjusted*
Adjusted for RPP**
Adjusted for HR**
1.82 ± 0.44
1.81 ± 0.04
1.82 ± 0.04
2.40 ± 0.74
2.38 ± 0.07
2.34 ± 0.07
<0.0001
Midventricular MPRI
Unadjusted*
Adjusted for RPP**
Adjusted for HR**
1.82 ± 0.52
1.79 ± 0.04
1.81 ± 0.04
2.38 ± 0.76
2.34 ± 0.07
2.30 ± 0.07
<0.0001
*Mean ± standard deviation
**Mean ± standard error
